The European Commission's Joint Research Centre (JRC) has published risk assessment test recommendations for nanomaterials based off the results of in-vitro testing of six nanomaterials as part of a recent study in PLOS One. The authors stated that any intelligent testing strategy that aims to accurately assess nanomaterial risks should include:
- "Cellular systems with biological relevance for targets in the human body (more than one target), including more sensitive cell models (such as macrophages) that can detect possible adverse effects at low doses that are potentially more relevant for human exposure;
- Reliable test assays, with no NMs interferences, designed to capture relevant mechanisms of toxicity. In addition, more complex test methods (i.e. embryonic stem cell test) and labelfree test methods (e.g. the TEER method for barrier integrity) should also be considered;
- Thorough physico-chemical characterization of NMs in order to interpret the toxicity data; indeed, further studies of structure-activity relationships of NMs are needed, and the present, comprehensive study provides a rich source of data for such QSAR-modeling."
The study was conducted as part of the FP7-MARINA project.